Cardiff Oncology, Inc. (CRDF) stock
CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.85−0.04 (-4.46%)
Close on Nov 20, 2026Market cap $66.34MP/E –Yield –
Cardiff Oncology profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Cardiff Oncology's profit margin for the twelve months ending Jun 30, 2026 was -7884.1%. For fiscal 2025 it was -7732.0%, against -6651.7% the year before. The highest annual figure on record is -868.9% in fiscal 2011.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -7732.0% | −1080.4 |
| FY2024 | Dec 31, 2024 | -6651.7% | +1840.3 |
| FY2023 | Dec 31, 2023 | -8492.0% | +1534.9 |
| FY2022 | Dec 31, 2022 | -10026.9% | −2146.4 |
| FY2021 | Dec 31, 2021 | -7880.5% | −2605.4 |
| FY2020 | Dec 31, 2020 | -5275.1% | +1434.6 |
| FY2019 | Dec 31, 2019 | -6709.7% | −2358.7 |
| FY2018 | Dec 31, 2018 | -4351.1% | +577.0 |
| FY2017 | Dec 31, 2017 | -4928.1% | +5359.7 |
| FY2016 | Dec 31, 2016 | -10287.7% | −1505.8 |
| FY2015 | Dec 31, 2015 | -8782.0% | −3669.0 |
| FY2014 | Dec 31, 2014 | -5113.0% | −557.1 |
| FY2013 | Dec 31, 2013 | -4555.9% | −1988.0 |
| FY2012 | Dec 31, 2012 | -2567.9% | −1699.0 |
| FY2011 | Dec 31, 2011 | -868.9% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -8876.9% | +2646.2 |
| Q1 FY2026 | Mar 31, 2026 | -30109.8% | −17785.0 |
| Q4 FY2025 | Dec 31, 2025 | -2969.5% | +4836.4 |
| Q3 FY2025 | Sep 30, 2025 | -9381.7% | −2196.8 |
| Q2 FY2025 | Jun 30, 2025 | -11523.1% | −4297.4 |
| Q1 FY2025 | Mar 31, 2025 | -12324.8% | −7441.4 |
| Q4 FY2024 | Dec 31, 2024 | -7806.0% | −1820.7 |
| Q3 FY2024 | Sep 30, 2024 | -7184.8% | −283.4 |
| Q2 FY2024 | Jun 30, 2024 | -7225.8% | +3098.3 |
| Q1 FY2024 | Mar 31, 2024 | -4883.4% | +8638.3 |
| Q4 FY2023 | Dec 31, 2023 | -5985.3% | +809.3 |
| Q3 FY2023 | Sep 30, 2023 | -6901.4% | +2314.7 |
| Q2 FY2023 | Jun 30, 2023 | -10324.1% | +1151.8 |
| Q1 FY2023 | Mar 31, 2023 | -13521.7% | +1333.7 |
| Q4 FY2022 | Dec 31, 2022 | -6794.5% | +304.7 |
| Q3 FY2022 | Sep 30, 2022 | -9216.1% | −1177.8 |
| Q2 FY2022 | Jun 30, 2022 | -11475.8% | −1539.1 |
| Q1 FY2022 | Mar 31, 2022 | -14855.4% | −7662.3 |
| Q4 FY2021 | Dec 31, 2021 | -7099.2% | −1555.6 |
| Q3 FY2021 | Sep 30, 2021 | -8038.4% | −4731.8 |
| Q2 FY2021 | Jun 30, 2021 | -9936.8% | −346.1 |
| Q1 FY2021 | Mar 31, 2021 | -7193.1% | −1179.8 |
| Q4 FY2020 | Dec 31, 2020 | -5543.7% | −961.0 |
| Q3 FY2020 | Sep 30, 2020 | -3306.6% | +4706.1 |
| Q2 FY2020 | Jun 30, 2020 | -9590.7% | +1166.8 |
| Q1 FY2020 | Mar 31, 2020 | -6013.2% | +282.6 |
| Q4 FY2019 | Dec 31, 2019 | -4582.7% | +747.6 |
| Q3 FY2019 | Sep 30, 2019 | -8012.7% | −3746.6 |
| Q2 FY2019 | Jun 30, 2019 | -10757.5% | −7406.5 |
| Q1 FY2019 | Mar 31, 2019 | -6295.9% | −1516.2 |
| Q4 FY2018 | Dec 31, 2018 | -5330.4% | −3941.5 |
| Q3 FY2018 | Sep 30, 2018 | -4266.1% | −786.0 |
| Q2 FY2018 | Jun 30, 2018 | -3351.1% | +4536.1 |
| Q1 FY2018 | Mar 31, 2018 | -4779.7% | +5741.9 |
| Q4 FY2017 | Dec 31, 2017 | -1388.9% | +11181.2 |
| Q3 FY2017 | Sep 30, 2017 | -3480.1% | +7970.8 |
| Q2 FY2017 | Jun 30, 2017 | -7887.2% | – |
| Q1 FY2017 | Mar 31, 2017 | -10521.6% | – |
| Q4 FY2016 | Dec 31, 2016 | -12570.1% | – |
| Q3 FY2016 | Sep 30, 2016 | -11450.9% | – |
See a number that looks wrong?